Onego Bio Submits GRAS Notification to FDA for Animal-Free Egg White Protein Bioalbumen

Finnish-American food ingredient company Onego Bio has submitted a Generally Recognized as Safe (GRAS) notification to the U.S. Food and Drug Administration (FDA) for its animal-free ovalbumin, called Bioalbumen®. This protein, replicated through precision fermentation using the fungus Trichoderma reesei, has the same properties as natural ovalbumin and can be used across various applications, offering a more sustainable and resilient alternative to conventional egg proteins. The environmental impact of Bioalbumen is significantly lower than that of traditional eggs, reducing greenhouse gas emissions, land use, and water consumption.

Onego Bio's recent submission follows the opening of its commercial headquarters in San Diego and a significant funding round. With a focus on North American market commercialization, the company aims to provide a solution to supply chain issues and contribute to a more sustainable food system. CEO Maija Itkonen emphasizes the importance of building a resilient supply chain and addressing future risks and price fluctuations by supplementing traditional agricultural inputs with innovative, sustainable alternatives like Bioalbumen.